Goldman Sachs analyst Chris Shibutani upgraded BioNTech (NASDAQ: BNTX) from Neutral to Buy with a price target of $137.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE